Danish pharmaceutical leader Novo Nordisk has transformed a legal confrontation with the telemedicine provider Hims & Hers into a collaborative venture. The ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side ...

Novo Nordisk has signed an agreement with Hims & Hers Health that will allow the telehealth provider to offer FDA‑approved versions of Ozempic and Wegovy at self‑pay prices comparable to other digital ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

Amid the company’s efforts to resolve issues raised during an FDA inspection early last year, Novo Nordisk’s operating base in Plainsboro, New Jersey—already the recipient of a recent Form 483—has ...

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped ...

HIMS stock has staged a sharp rebound after drugmaker Novo Nordisk dropped its lawsuit against the company. Is the stock now a buy?

Whether President Trump signaled that he may soon end the military strikes is weighing on the minds of investors, executives and others.

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Ozempic maker Novo Nordisk gets another downgrade. The end's in sight for its duopoly status, says TD Cowen. TD Cowen downgraded Novo Nordisk to hold. Novo Nordisk on Tuesday received a broker ...